Search clinical trials for: Neulasta (pegfilgrastim)

Total 326 results

Teva Branded Pharmaceutical Products R&D, Inc.

Completed

A comparatiVe Study on Efficacy and Safety of Lipegfilgrastim in Comparison to Pegfilgrastim in Elderly Patients With Aggressive B Cell Non-HOdgkin Lymphomas at hIgh Risk for R-CHOP-21-inDuced Neutropenia (AVOID)

Aggressive B Cell Non-Hodgkin Lymphomas at High Risk for R-CHOP-21-induced Neutropenia

Germany, Italy, Spain
Coherus Biosciences, Inc.

Completed

Assessing the Immunogenicity of 2 Subcutaneous Doses of CHS-1701 (Coherus Pegfilgrastim) With 2 Subcutaneous Doses Neulasta®

Immunity, Humoral

United States
Dartmouth-Hitchcock Medical Center

Terminated

Feasibility and Cost Analysis of PBSC Mobilization Using Pegfilgrastim in Hematologic Malignancies

Hematologic Malignancies

United States
Coherus Biosciences, Inc.
Community Clinical Oncology Research Network, LLC

Unknown

An Analysis to Estimate Febrile Neutropenia (FN) in Patients Receiving Udenyca (POEM)

Febrile Neutropenia | Non-myeloid Malignancy

United States
Amgen

Completed

A Study of Primary Prophylaxis With Neulasta (Pegfilgrastim) Versus Secondary Prophylaxis After Chemotherapy in Elderly Subjects (>/= 65 Years Old) With Cancer

Breast Cancer | Non-Hodgkin's Lymphoma | Ovarian Cancer | Lung Cancer | Neutropenia
University Hospital, Clermont-Ferrand
Amgen

Unknown

Pegfilgrastim for Stem Cell Mobilization in Children (Meg-5) (MEG-5)

Solid Malignancies

France
Amgen

Completed

Neulasta® in Subjects With Advanced Non-Small-Cell Lung Cancer (NSCLC) During Chemotherapy

Non-Small Cell Lung Cancer
Hospital Universitario Dr. Jose E. Gonzalez

Completed

Efficacy of Generic Pegfilgrastim vs Brand Name Pegfilrastim for Neutrophil Recovery After Autotransplant

Lymphoma | Myeloma Multiple

Mexico
Fresenius Kabi SwissBioSim GmbH

Completed

Pharmacokinetic/Pharmacodynamic Equivalence of MSB11455 in Healthy Subjects

Healthy

Australia
EVIVE Biotechnology

Completed

Neulasta-controlled Trial of F-627 in Women With Breast Cancer Receiving Myelotoxic Chemotherapy

Breast Cancer | Neutropenia

United States
Qilu Pharmaceutical Co., Ltd.

Unknown

A Phase 1 Study to Assess the Immunogenicity of QL0605 Compared to US Neulasta in Healthy Subjects

Healthy

Germany, United Kingdom
Coherus Biosciences, Inc.

Completed

Study to Assess the Pharmacokinetic and Pharmacodynamic Bioequivalence of CHS-1701 With Neulasta

Healthy

United States
Coherus Biosciences, Inc.

Completed

Comparison of the Pharmacokinetic and Pharmacodynamic Biosimilarity of CHS-1701 (Coherus Pegfilgrastim) With Neulasta® (Pegfilgrastim)

Bioequivalence

United States
Green Cross Corporation
Symyoo

Completed

GCPGC in Chemotherapy-induced Neutropenia

Chemotherapy Induced Neutropenia

Korea, Republic of
Fresenius Kabi SwissBioSim GmbH

Completed

Safety and Immunogenicity of MSB11455 in Healthy Participants

Healthy

New Zealand
Hospira, now a wholly owned subsidiary of Pfizer

Completed

Pharmacokinetic/Pharmacodynamic (PK/PD) Study Evaluating Pegfilgrastim Hospira Compared to Neulasta (Amgen) in Healthy Volunteers

Healthy

United Kingdom
Sandoz
Sandoz GmbH

Completed

Phase III Study Comparing the Efficacy and Safety of LA-EP2006 and Peg-Filgrastim (PROTECT2)

Breast Cancer | Chemotherapy-induced Neutropenia

Spain, United States, Argentina, Chile, India, Malaysia, Puerto Rico, Russian Federation
Gedeon Richter Plc.

Completed

Study to Compare the Pharmacokinetics and Pharmacodynamics of 6 mg RGB-02 to 6 mg Neulasta

Bioequivalence

United Kingdom
Rabin Medical Center
Tel-Aviv Sourasky Medical Center; Soroka University Medical Center

Unknown

Pegfilgrastim on Day +3 Compared to Day +1 After Salvage Chemotherapy for Patients With Refractory or Relapsed Aggressive Lymphoma

Lymphoma | Neutropenia

Israel
University Hospital Tuebingen

Completed

Pegfilgrastim vs. Filgrastim - Comparison of Mobilized Blood Stem Cells in Patients With Non Hodgkin-lymphoma

Non-Hodgkin Lymphoma

Germany
M.D. Anderson Cancer Center
Amgen

Completed

Pegfilgrastim (Neulasta) for Stem Cell Mobilization in Patients With Multiple Myeloma

Multiple Myeloma

United States
Buddhist Tzu Chi General Hospital

Recruiting

The Neuroprotective Effect of PEG-GCSF in the Traumatic Optic Neuropathy

Traumatic Optic Neuropathy

Taiwan
Nanogen Pharmaceutical Biotechnology Joint Stock...

Completed

Nanogen Pegcyte Clinical Study for the Prevention of CIN in Breast-cancer Patients.

Breast Cancer Female

Vietnam
Adello Biologics, LLC
Celerion

Completed

Comparative Immunogenicity Study Comparing TPI-120 to Neulasta® in Healthy Adult Subjects (TPI-120)

Healthy Volunteers

United States
Sandoz
Sandoz GmbH

Completed

Phase III Study Comparing the Efficacy and Safety of LA-EP2006 and Neulasta® (PROTECT-1)

Breast Neoplasms | Chemotherapeutic Toxicity | Chemotherapy-induced Neutropenia | Neutropenic Complications

Russian Federation, Brazil, India, Mexico, Romania, Ukraine
Hoffmann-La Roche

Completed

An Expanded Access Program of Pegfilgrastim (Neulastim) in Participants With Non-Hodgkin's Lymphoma (NHL)

Non-Hodgkin's Lymphoma

Colombia, Mexico
Pfizer
Hospira, now a wholly owned subsidiary of Pfizer

Completed

A Comparative Study to Evaluate the Effect of HSP-130, US-approved Neulasta and EU-approved Neulasta in Healthy Participants

Neutropenia

Australia
Megalabs

Recruiting

Biosimilarity Study of Subcutaneous Pegfilgrastim in Healthy Volunteers

Neutropenia

Brazil
Lupin Ltd.

Completed

Immunogenicity Assessment of Peg-filgrastim vs. Neulasta® as Adjunct to Chemotherapy in Patients With Breast Cancer

Breast Cancer

India
Adello Biologics, LLC
inVentiv Health Clinical

Completed

Study Comparing TPI-120 and Neulasta Administered Through Subcutaneous Route in Healthy Adult Subjects (TPI-120)

Healthy Volunteers

United States
EVIVE Biotechnology

Completed

Dose-Finding Trial of F-627 in Women With Breast Cancer Receiving Myelotoxic Chemotherapy

Breast Cancer | Neutropenia

United States
Eurofarma Laboratorios S.A.

Withdrawn

Trial to Compare the Efficacy and Safety of Pegfilgrastim Biosimilar in Subjects With High Risk Stage Breast Cancer Receiving Chemotherapy

Breast Cancer
Ottawa Hospital Research Institute

Active, not recruiting

A Randomized, Multicenter Pragmatic Trial Comparing Bone Pain From a Single Dose of Pegfilgrastim to 5 Doses of Daily Filgrastim in Breast Cancer Patients Receiving Neoadjuvant/Adjuvant Chemotherapy

Early-stage Breast Cancer

Canada
Armando Santoro, MD

Completed

Pegfilgrastim Versus Filgrastim After High-dose Chemotherapy

Tumors | Hematological Neoplasms

Italy
Mylan Inc.
Mylan GmbH

Completed

Pharmacokinetic / Pharmacodynamic Study Comparing MYL-1401H, EU-sourced Neulasta and US-licensed Neulasta

Healthy Volunteers

Netherlands
Sidney Kimmel Cancer Center at Thomas Jefferson...
Sanofi

Completed

Cabazitaxel in Patients With Urothelial Carcinoma Who Have Disease Progression Following Platinum-Based Chemotherapy

Urothelial Carcinoma

United States
SCRI Development Innovations, LLC
Celgene

Completed

A Trial of Amrubicin and Carboplatin With Pegfilgrastim in Patients With Extensive-Stage Small Cell Lung Cancer

Extensive-Stage Small Cell Lung Cancer

United States
BeyondSpring Pharmaceuticals Inc.
Covance; ICON plc

Completed

Plinabulin vs. Pegfilgrastim in Patients With Solid Tumors Receiving Docetaxel Myelosuppressive Chemotherapy Phase 3 (Protective-1)

Chemotherapy-induced Neutropenia

China, Russian Federation, United States, Ukraine
Centre Leon Berard
Amgen

Terminated

Lymphocyte Reconstitution After Administration of Pegfilgrastim Versus Filgrastim After Peripheral Stem Cell Transplantation (PALM2)

Non Hodgkin Lymphoma

France
Biologics & Biosimilars Collective Intelligence...
Henry Ford Health System; HealthPartners Institute; Amgen; Aetna, Inc.; Harvard Pilgrim... and other collaborators

Completed

Descriptive Analysis of G-CSF Use in Patients With Breast Cancer, Lung Cancer, or Lymphoma Treated

Breast Cancer | Lung Cancer
AstraZeneca

Terminated

A Placebo Controlled Study Comparing AZD1775+ Docetaxel Versus Placebo+Docetaxel to Treat Lung Cancer

Previously Treated Non Small Cell Lung Cancer

United States
University Hospital Inselspital, Berne

Completed

Peg-Granulocyte-Colony Stimulating Factor (GCSF) for Coronary Collateral Growth in Coronary Artery Disease Patients

Coronary Artery Disease

Switzerland
University of Michigan Rogel Cancer Center
Baylor College of Medicine; Merck Sharp & Dohme LLC; Dana-Farber Cancer Institute and other collaborators

Completed

Phase I/II Study of MK-0752 Followed by Docetaxel in Advanced or Metastatic Breast Cancer

Metastatic Breast Cancer

United States
Western Regional Medical Center

Terminated

Dacarbazine and Carmustine in Metastatic Melanoma

Melanoma Metastatic

United States
Duke University
Sanofi

Terminated

Dose-Dense Induction/Neoadjuvant Chemotherapy in Locally Advanced Non-Small Cell Lung Cancer

Non-small Cell Lung Cancer

United States
Mylan Inc.
Mylan GmbH

Completed

Efficacy and Safety Study With MYL-1401H and Neulasta

Breast Neoplasms | Chemotherapy-Induced Febrile Neutropenia

Bulgaria, Georgia, Germany, Hungary, Poland, Ukraine
Dana-Farber Cancer Institute

Completed

Avoiding Growth Factor During Paclitaxel Treatment in Breast Cancer

Early Stage Breast Cancer

United States
Sidney Kimmel Comprehensive Cancer Center at Johns...
National Cancer Institute (NCI)

Terminated

Neoadjuvant Docetaxel in Treating Women With Newly Diagnosed Breast Cancer

Breast Cancer

United States
Centre Leon Berard
Amgen

Recruiting

Impact of Pegfilgrastim on Trastuzumab Anti-tumor Effect and ADCC in Operable HER2+ Breast Cancer Breast Cancer (BREASTIMMU02)

HER2-positive Breast Cancer | Operable Breast Cancer

France
Dr. Reddy's Laboratories Limited

Unknown

A Comparative, Crossover, Pharmacokinetic, Pharmacodynamic and Safety Study of Three Forms of PEG-G-CSF in Normal Healthy Volunteers

Pharmacokinetics

United States

3

Subscribe